The Full Story in Plain English
What the Study Found (In Plain English)
Why This Matters to You
Official journal of the European Federation for Pharmaceutical Sciences (2021), this phase iii randomized trial evaluating human clinical outcomes investigated: In the last update of the RECIST criteria in 2009, it was proposed that the number of target lesions to be followed over time for response-to-treatment assessment be reduced from 10 to 5 lesions maximum, with up to 2 per organ. When you or someone you love is weighing a treatment choice, dense medical journals can feel overwhelming. Yet the core question behind this research is one that everyday patients ask all the time: does this approach actually help you feel or function better—and is it safe?
How the Study Worked
To find out, researchers writing in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences conducted a phase iii randomized trial evaluating multiple clinical patient groups. Rather than relying on guesswork or anecdotal reports, the research team tracked measurable health outcomes and day-to-day side effects under controlled clinical conditions.
What the Study Found in Plain English
Including how the body absorbs the medicine metrics in TGI models should be conducted carefully when no how the body absorbs the medicine samples are available. Reducing the number of target lesion did not seem to compromise the. Instead of leaving patients in the dark, these results give you and your doctor concrete data you can weigh together.
The Catch: What to Keep in Mind
Even strong medical studies have limits. Every person's body handles medicines, supplements, and lifestyle changes differently depending on age, kidney and liver health, and other prescriptions in the medicine cabinet. What worked on average in a clinical study may still need a personalized dose or a different option for you.
Bottom Line: Your Next Step
Bring this summary to your next doctor or pharmacist visit. Ask: "Based on my health history and current medications, does this research apply to me?" You can also click the formal study link below to inspect the original peer-reviewed paper directly.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Published in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences (2021-06-01) • Study Design: Phase III Randomized Trial • Participants: Pooled Clinical Review • Biostatistical Rigor Score: 82/100. Primary Takeaway: Including how the body absorbs the medicine metrics in TGI models should be conducted carefully when no how the body absorbs the medicine samples are available.
Study Limitations & Caveats Before You Act
While this phase iii randomized trial scored 82/100 for research quality, clinical trials follow strict rules that may not match every patient's daily life. Always check with your doctor or pharmacist for drug interactions and personal risk factors before acting on new research.
Formal Peer-Reviewed Study Reference
“Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed”
Published in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences (2021-06-01) • PMID/ID: 33667665